 |
| june
1, 2026 |
| Regional
intelligence on Drugs, Diagnostics,
Devices & Digital Health |
|
|
|
* may need subscription to view |
|
BIG4BIO
WEEKLY CEO Q&A:
Robin Toft, CEO, Curebound |
|
In this Q&A, Robin talks about her
career pivot into the nonprofit sector,
the collaborative research model that sets
Curebound apart, the growing role of
philanthropic capital to fill funding
gaps, and what it takes to build both a
high-performing team and a research
accelerator with staying power. More |
|
|
 |
| Biotech’s
most flexible vivarium lab space
to launch and scale studies. |
|
Learn More
→ |
|
|
- Aura Biosciences: Enrollment Completion in
Phase 3 CoMpass Trial of Bel-sar in Early
Choroidal Melanoma More
- Cogent Biosciences: Detailed Clinical Data
From PEAK Phase 3 Trial With Bezuclastinib in
Combination With Sunitinib in Gastrointestinal
Stromal Tumors (GIST) at 2026 American Society
of Clinical Oncology (ASCO) Annual Meeting More
- Dana-Farber Cancer Institute: Addition of
Mezigdomide to Standard Therapy Significantly
Improves Outcomes in Relapsed Refractory
Multiple Myeloma More
- Decoy Therapeutics: Partners With hVIVO to
Advance Lead D-MAV Candidate Into the Clinic More
- Elicio Therapeutics: Publication in
Peer-Reviewed Journal Science Advances
Highlighting Potent and Durable Immune
Responses Driven by Company’s AMP-DNA Adjuvant
Technology More
- Foundation Medicine: Launches FoundationOne
MRD, First-of-Its-Kind Molecular Residual
Disease Test to Combine Structural Variants
and Digital PCR More
- Foundation Medicine: US FDA Approves
FoundationOneCDx and FoundationOneLiquid CDx
as Companion Diagnostics for TALZENNA
(talazoparib) in Combination With XTANDI
(enzalutamide) to Identify Patients With HRR
Gene-Mutated Metastatic Castration-Resistant
Prostate Cancer More
- Fractyl Health: Appoints Mike Zumdahl as
Senior Vice President, Market Access and
Commercial Strategy More
- Kelonia Therapeutics: Updated First-in-Human
Data From Phase 1 inMMyCAR Study of KLN-1010
in vivo BCMA CAR-T Therapy at the 2026
American Society of Clinical Oncology (ASCO)
Annual Meeting More
- Lysoway Therapeutics: Awarded Grant From The
Michael J. Fox Foundation to Advance TMEM175
Agonists for Parkinson’s Disease More
- Precede Biosciences: New ASCO 2026 Data
Demonstrating Ability of Precede Bio Insight
to Decode MET-Driven Biology and Resistance in
Advanced NSCLC More
- Ranok Therapeutics: Positive Interim Phase 1
Data Of Its KRAS G12D Inhibitor RNK08954 in
Patients With KRAS G12D-Mutated Metastatic
Non-Small Cell Lung Cancer Presented At ASCO
2026 More
- Ratio Therapeutics and PharmaLogic: Expand
Manufacturing Collaboration to Support
Clinical Development of [Ac-225]RTX-2358 More
- Replimune: Final First-in-Human Data for
RP2 in Advanced Solid Tumors During Oral
Presentation at the 2026 American Society of
Clinical Oncology Annual Meeting More
- Replimune: 3-Year Landmark Overall
Survival Analysis From IGNYTE Clinical Trial
During Oral Presentation at the 2026
American Society of Clinical Oncology Annual
Meeting More
- Sumitomo
Pharma America: Presents First Clinical Data
for SMP-3124LP, an Investigational PEGylated
Liposome CHK1 Inhibitor, at ASCO 2026 More
- Thermo Fisher Scientific: Expands Orbitrap
Innovation Across Research, Biopharma and
Applied Testing at ASMS 2026 More
- UCB and Biogen: Publication in The Lancet of
Positive Dapirolizumab Pegol (DZP) Phase 3
Study Results in Systemic Lupus Erythematosus
More
- Vertex: US FDA Acceptance of Biologics
License Application for Accelerated Approval
of Povetacicept in IgA Nephropathy More
- Voyager: Receives FDA IND Clearance for
VY1706, First Gene Therapy Approach to
Reducing Tau Production in the Brain for
Alzheimer’s Disease More
|
|
 |
Charles
River CFO
Keeping It Steady During a
Company-Defining Moment |
|
Learn More
→ |
|
|
- Agios: Enters Exclusive Global License
Agreement With Oscotec to Develop and
Commercialize Next-Generation SYK Inhibitor
Cevidoplenib More
- Crescent Biopharma: Grants of Inducement
Awards More
- Damora Therapeutics: Inducement Grants Under
Nasdaq Listing Rule 5635(c)(4) More
- From Seed to Series C: What Investors Look
for Beyond the Science More
- Moderna and CEPI: Expand Strategic
Collaboration to Advance Potential Vaccine
Against Bundibugyo Ebolavirus More
- XtalPi: Receives Second Payment From
DoveTree; First Oncology Asset Advances Into
IND-Enabling Studies More
- Zevra Therapeutics: Inducement Grants Under
Nasdaq Listing Rule 5635(c)(4) More
|
|
|
 |
Pace®
Life Sciences
The CDMO That Takes You Further.
Your partner for Product
Development, Manufacturing,
Analytical Testing, Regulatory
Consulting & Operational
Support. |
|
Learn More
→ |
|
|
- Big4Bio CEO Weekly Q&A: Robin Toft,
CEO, Curebound More
- Biotech Hangout: Episode 184 Podcast
- Bonito Biosciences and DaltonTx Collaborate
on Precision Delivery for Oligotherapeutics
More
- Boston, China and the Future of Biotech Podcast
- More on Agios Ending Development of
Tebapivat in Low-Risk MDS Following Subpar
Results More*
More
More
- More on Replimune Asking FDA for
Re-Review of Melanoma Drug, as Agency Stands
by Past Rejections More*
More
- Subscribe to LifeSci Startup for
Updates on US Startups More
|
|
- Telling Your Science Story to
Investors More
- AI in Biotech: The New
Frontier for Leadership & Strategy More
- David Chang to Hand Over the Reins at
Allogene; Ex-Esperion CEO Gets Started at
Phlow More*
- Empowering Students Through STEM: A
Conversation With Massachusetts Science &
Engineering Fair Executive Director Helen
Rosenfeld More
- Hiring Outlook: Job Opportunities on
BioSpace Rise YOY, but Layoffs Affect
Thousands More
- M&A in Life Sciences: The Turning Tide –
Why Now is a Strategic Inflection for
Biopharma and Biotech More
- More Than Executive Search: Building
Leadership for Every Stage of Growth More
- Opportunity: President, Business
Development, New England Region, Remote More
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: Boston Life Science
Company Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:Boston,
all rights reserved 2026
© 2026
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
